Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Drug repositioning [[electronic resource] ] : bringing new life to shelved assets and existing drugs / / edited by Michael J. Barratt, Donald E. Frail
| Drug repositioning [[electronic resource] ] : bringing new life to shelved assets and existing drugs / / edited by Michael J. Barratt, Donald E. Frail |
| Pubbl/distr/stampa | Hoboken, : John Wiley & Sons, c2012 |
| Descrizione fisica | 1 online resource (499 p.) |
| Disciplina | 338.4/76151 |
| Altri autori (Persone) |
BarrattMichael J
FrailDonald |
| Soggetto topico |
Pharmaceutical industry - Economic aspects
Drugs - Economic aspects |
| ISBN |
1-118-27439-3
1-118-27440-7 1-280-69675-3 9786613673718 1-118-27437-7 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Drug repositioning : the business case and current strategies to repurpose shelved candidates and marketed drugs / John Arrowsmith and Richard Harrison -- Opportunities and challenges associated with developing additional indications for clinical development candidates and marketed drugs / Donald Frail and Michael Barratt -- Clinical and operational considerations in repositioning marketed drugs and drug candidates / Damian O'Connell, David Sequeira, and Maria Miller -- Regulatory considerations and strategies for drug repositioning / Ken Phelps -- Computational and bioinformatic strategies for drug repositioning / Richard Mazzarella and Craig Webb -- Mining scientific and clinical databases to identify novel uses for existing drugs / Christos Andronis ... [et al.] -- Predicting the polypharmacology of drugs : identifying new uses through chemoinformatics, structural informatics and molecular modeling based approaches / Li Xie ... [et al.] -- Systematic phenotypic screening for novel synergistic combinations: a new paradigm for repositioning existing drugs / Margaret Lee -- Phenotypic in vivo screening to identify new, unpredicted indications for existing drugs and drug candidates / Michael Saporito, Christopher Lipinski, and Andrew Reaume -- Old drugs yield new discoveries : examples from the prodrug, chiral switch and site-selective deuteration strategies / Adam Morgan ... [et al.] -- Repurposing drugs for tropical diseases : case studies and open-source screening initiatives / Curtis Chong -- Drug repositioning efforts by non-profit foundations -- Business development strategies in the repositioning industry / Aris Persidis and Elizabeth Stark -- A case study in drug repositioning : Sosei / Akinori Mochizuki and Makiko Aoyama. |
| Record Nr. | UNINA-9910141262403321 |
| Hoboken, : John Wiley & Sons, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug repositioning : bringing new life to shelved assets and existing drugs / / edited by Michael J. Barratt, Donald E. Frail
| Drug repositioning : bringing new life to shelved assets and existing drugs / / edited by Michael J. Barratt, Donald E. Frail |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, : John Wiley & Sons, c2012 |
| Descrizione fisica | 1 online resource (499 p.) |
| Disciplina | 338.4/76151 |
| Altri autori (Persone) |
BarrattMichael J
FrailDonald |
| Soggetto topico |
Pharmaceutical industry - Economic aspects
Drugs - Economic aspects |
| ISBN |
9786613673718
9781118274392 1118274393 9781118274408 1118274407 9781280696756 1280696753 9781118274378 1118274377 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Drug repositioning : the business case and current strategies to repurpose shelved candidates and marketed drugs / John Arrowsmith and Richard Harrison -- Opportunities and challenges associated with developing additional indications for clinical development candidates and marketed drugs / Donald Frail and Michael Barratt -- Clinical and operational considerations in repositioning marketed drugs and drug candidates / Damian O'Connell, David Sequeira, and Maria Miller -- Regulatory considerations and strategies for drug repositioning / Ken Phelps -- Computational and bioinformatic strategies for drug repositioning / Richard Mazzarella and Craig Webb -- Mining scientific and clinical databases to identify novel uses for existing drugs / Christos Andronis ... [et al.] -- Predicting the polypharmacology of drugs : identifying new uses through chemoinformatics, structural informatics and molecular modeling based approaches / Li Xie ... [et al.] -- Systematic phenotypic screening for novel synergistic combinations: a new paradigm for repositioning existing drugs / Margaret Lee -- Phenotypic in vivo screening to identify new, unpredicted indications for existing drugs and drug candidates / Michael Saporito, Christopher Lipinski, and Andrew Reaume -- Old drugs yield new discoveries : examples from the prodrug, chiral switch and site-selective deuteration strategies / Adam Morgan ... [et al.] -- Repurposing drugs for tropical diseases : case studies and open-source screening initiatives / Curtis Chong -- Drug repositioning efforts by non-profit foundations -- Business development strategies in the repositioning industry / Aris Persidis and Elizabeth Stark -- A case study in drug repositioning : Sosei / Akinori Mochizuki and Makiko Aoyama. |
| Record Nr. | UNINA-9910820493303321 |
| Hoboken, : John Wiley & Sons, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : workshop summary / / Sheena M. Posey Norris [and three others], rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy
| Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : workshop summary / / Sheena M. Posey Norris [and three others], rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy |
| Autore | Norris Sheena M. Posey |
| Pubbl/distr/stampa | Washington, District of Columbia : , : The National Academies Press, , 2015 |
| Descrizione fisica | 1 online resource (128 p.) |
| Disciplina | 615 |
| Soggetto topico |
Pharmaceutical industry - Economic aspects
Drug development - Economic aspects Central nervous system - Diseases - Effect of drugs on Public-private sector cooperation |
| ISBN |
0-309-37326-3
0-309-37324-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | FrontMatter; Reviewers; Contents; 1 Introduction and Overview; 2 Improving Market Protection; 3 Strengthening the Regulatory Pathway; 4 Patient Benefit and Engagement; Appendix A: References; Appendix B: Workshop Agenda; Appendix C: Registered Attendees; Appendix D: Participant Biographies |
| Record Nr. | UNINA-9910797749603321 |
Norris Sheena M. Posey
|
||
| Washington, District of Columbia : , : The National Academies Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : workshop summary / / Sheena M. Posey Norris [and three others], rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy
| Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : workshop summary / / Sheena M. Posey Norris [and three others], rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy |
| Autore | Norris Sheena M. Posey |
| Pubbl/distr/stampa | Washington, District of Columbia : , : The National Academies Press, , 2015 |
| Descrizione fisica | 1 online resource (128 p.) |
| Disciplina | 615 |
| Soggetto topico |
Pharmaceutical industry - Economic aspects
Drug development - Economic aspects Central nervous system - Diseases - Effect of drugs on Public-private sector cooperation |
| ISBN |
0-309-37326-3
0-309-37324-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | FrontMatter; Reviewers; Contents; 1 Introduction and Overview; 2 Improving Market Protection; 3 Strengthening the Regulatory Pathway; 4 Patient Benefit and Engagement; Appendix A: References; Appendix B: Workshop Agenda; Appendix C: Registered Attendees; Appendix D: Participant Biographies |
| Record Nr. | UNINA-9910808601903321 |
|
Norris Sheena M. Posey
|
||
| Washington, District of Columbia : , : The National Academies Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : workshop summary / / Sheena M. Posey Norris [and three others], rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy
| Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : workshop summary / / Sheena M. Posey Norris [and three others], rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy |
| Pubbl/distr/stampa | Washington, District of Columbia : , : The National Academies Press, , 2015 |
| Descrizione fisica | 1 online resource (128 p.) |
| Disciplina | 615 |
| Soggetto topico |
Pharmaceutical industry - Economic aspects
Drug development - Economic aspects Central nervous system - Diseases - Effect of drugs on Public-private sector cooperation |
| Soggetto genere / forma | Electronic books. |
| ISBN | 0-309-37324-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | FrontMatter; Reviewers; Contents; 1 Introduction and Overview; 2 Improving Market Protection; 3 Strengthening the Regulatory Pathway; 4 Patient Benefit and Engagement; Appendix A: References; Appendix B: Workshop Agenda; Appendix C: Registered Attendees; Appendix D: Participant Biographies |
| Record Nr. | UNINA-9910480296503321 |
| Washington, District of Columbia : , : The National Academies Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Journal of Health Policy & Outcomes Research
| Journal of Health Policy & Outcomes Research |
| Pubbl/distr/stampa | Warszawa, Poland : , : Fundacja Pro Medicina, , [2012]- |
| Descrizione fisica | 1 online resource |
| Soggetto topico |
Medical policy
Outcome assessment (Medical care) Outcome assessment (Medical care) - Cost effectiveness Pharmacology - Economic aspects Pharmaceutical industry - Economic aspects Health Policy Economics, Pharmaceutical Drug Therapy - economics Cost-Benefit Analysis Outcome Assessment, Health Care |
| Soggetto genere / forma |
Periodical
Periodicals. |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti |
JHPOR
Journal of health policy and outcomes research |
| Record Nr. | UNINA-9910895142903321 |
| Warszawa, Poland : , : Fundacja Pro Medicina, , [2012]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Medicine price surveys, analyses and comparisons : evidence, methodology and guidance / / edited by Sabine Vogler
| Medicine price surveys, analyses and comparisons : evidence, methodology and guidance / / edited by Sabine Vogler |
| Pubbl/distr/stampa | London, England : , : Elsevier, , 2019 |
| Descrizione fisica | 1 online resource (490 pages) |
| Disciplina | 338.436151 |
| Soggetto topico |
Drugs - Prices
Pharmaceutical industry - Economic aspects Drugs - Economic aspects |
| ISBN | 0-12-813212-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover -- MEDICINE PRICE SURVEYS, ANALYSES, AND COMPARISONS -- MEDICINE PRICE SURVEYS, ANALYSES, AND COMPARISONS -- Copyright -- Dedication -- CONTENTS -- CONTRIBUTORS -- ACKNOWLEDGEMENTS -- 1 - Introduction -- LIST OF ABBREVIATIONS -- 1.1 BACKGROUND AND RATIONALE -- 1.2 AIM AND OUTLINE -- 1.3 METHODOLOGY -- 1.4 TARGET AUDIENCE -- REFERENCES -- 1 - Evidence - Findings of Medicine Price Studies -- 2 - International Comparison of Medicine Prices -- LIST OF ABBREVIATIONS -- 2.1 - Medicine Prices in European Countries -- LIST OF ABBREVIATIONS -- 2.1.1 INTRODUCTION -- 2.1.2 HIGH-COST MEDICINES -- 2.1.2.1 Oncology -- 2.1.2.2 Hepatitis C -- 2.1.2.3 Rare Diseases -- 2.1.2.4 Concordance of Prices With Purchasing Power -- 2.1.3 GENERIC MEDICINES -- 2.1.4 IMPACT OF POLICY MEASURES -- 2.1.4.1 External Price Referencing -- 2.1.4.1.1 Challenges Related to External Reference Pricing -- 2.1.4.2 Convergence of Medicine Prices Over Time -- 2.1.5 ACTUAL PRICES -- 2.1.6 FINAL REMARKS -- REFERENCES -- 2.2 - Medicine Prices in the United States and Canada -- LIST OF ABBREVIATIONS -- 2.2.1 CANADA -- 2.2.1.1 Policies -- 2.2.1.1.1 Federal Patented Drug Price Regulation -- 2.2.1.1.2 Drug Plan Reimbursement of Brand Drugs -- 2.2.1.1.3 Drug Plan Reimbursement of Generic Drugs -- 2.2.1.1.4 Biosimilars -- 2.2.1.2 Canada Drug Price Studies -- 2.2.1.2.1 Brand Drugs -- 2.2.1.2.2 Biologics -- 2.2.1.2.3 Generics -- 2.2.1.2.4 All Prescribed Drugs -- 2.2.2 UNITED STATES -- 2.2.2.1 Policies -- 2.2.2.2 US Price Studies -- 2.2.2.2.1 Generics -- 2.2.3 CONCLUSION -- REFERENCES -- 2.3 - Medicine Prices in Asia-Pacific Countries -- LIST OF ABBREVIATIONS -- 2.3.1 INTRODUCTION -- 2.3.2 PRICE STUDIES FOR SPECIFIC MEDICINES GROUPS -- 2.3.2.1 High-Cost Medicines -- 2.3.2.2 Medicines for Cancer -- 2.3.2.3 Medicines for Central Nervous System-Related Diseases.
2.3.2.4 Medicines for Hepatitis C -- 2.3.2.5 Antiretroviral Medicines -- 2.3.2.6 Generic Medicines -- 2.3.3 CONCORDANCE OF PRICES WITH AFFORDABILITY -- 2.3.3.1 China (Upper Middle-Income Country) -- 2.3.3.2 Sri Lanka (Lower Middle-Income Country) -- 2.3.3.3 Malaysia (Upper Middle-Income Country) -- 2.3.4 IMPACT OF POLICY MEASURES -- 2.3.5 FINAL REMARKS -- REFERENCES -- 2.4 - Medicine Prices in Latin American Countries -- LIST OF ABBREVIATIONS -- 2.4.1 THE PRICE OF MEDICINES IN LATIN AMERICAN COUNTRIES -- 2.4.1.1 Introduction -- 2.4.1.2 Examples of Price Regulation in the Latin America Region -- 2.4.1.2.1 Colombian Medicines Pricing Regulation -- 2.4.1.2.2 Brazilian Medicines Pricing Regulation -- 2.4.1.2.3 Price Regulation in Other Latin American Countries -- 2.4.2 ONLINE SOURCES OF MEDICINES PRICES IN LATIN AMERICA -- 2.4.3 MEDICINE PRICE STUDIES IN LATIN AMERICAN COUNTRIES -- 2.4.3.1 Introduction -- 2.4.3.2 Methodology -- 2.4.3.3 Results and Findings -- 2.4.4 CONCLUSIONS -- REFERENCES -- FURTHER READING -- 2.5 - Medicine Prices in Africa -- LIST OF ABBREVIATIONS -- 2.5.1 INTRODUCTION -- 2.5.2 BACKGROUND TO HEALTH AND HEALTH SYSTEMS IN AFRICA -- 2.5.2.1 Growth in Sub-Saharan Africa -- 2.5.2.2 Health Care in Africa -- 2.5.2.3 Provision of Health Care in Africa -- 2.5.3 THE AFRICAN MEDICINES ENVIRONMENT -- 2.5.4 METHODS FOR SELECTING STUDIES ON PRICING AND AVAILABILITY -- 2.5.5 OVERVIEW OF FINDINGS -- 2.5.6 DISCUSSION ON MEDICINES AVAILABILITY AND PRICING IN AFRICA -- 2.5.6.1 Measurement of Availability of Medicines -- 2.5.6.2 Measurement of Availability and Price -- 2.5.6.3 Measurement of Pricing of Medicines -- 2.5.6.4 Multicountry Comparisons -- 2.5.7 CONCLUSIONS: SUMMARY AND WAY FORWARD -- 2.5.8 GAPS IN THE LITERATURE -- REFERENCES -- 3 - Price Studies for Specific Medicines -- LIST OF ABBREVIATIONS -- 3.1 GENERIC AND BIOSIMILAR MEDICINES. 3.2 HIGH-PRICED MEDICINES, INCLUDING ORPHAN MEDICINAL PRODUCTS -- 3.3 MEDICINES FOR SPECIFIC INDICATIONS -- 3.3.1 HIV/AIDS Medicines -- 3.3.2 Cancer Medicines -- 3.3.3 Hepatitis C Medicines -- 3.3.4 Further Indications -- 3.4 HOSPITAL MEDICINES -- 3.5 NON-PRESCRIPTION MEDICINES -- 3.6 CONCLUSION -- REFERENCES -- 4 - Studies of Medicine Price Developments -- LIST OF ABBREVIATIONS -- 4.1 IMPACT ASSESSMENT -- 4.2 NATIONAL STUDIES -- 4.3 CROSS-NATIONAL STUDIES -- REFERENCES -- 5 - Discussion and Summary -- LIST OF ABBREVIATIONS -- REFERENCES -- 2 - Training - How to Conduct Medicine Price Surveys, Analyses and Comparisons? -- 6 - Review of Methodologies to Conduct Price Studies -- LIST OF ABBREVIATIONS -- 6.1 - Overview of Existing Methodologies -- 6.2 - WHO/HAI Methodology for Measuring Medicine Prices, Availability and Affordability, and Price Components -- 6.2.1 BACKGROUND AND HISTORY -- 6.2.2 OBJECTIVE OF THE WORLD HEALTH ORGANIZATION/HEALTH ACTION INTERNATIONAL METHODOLOGY -- 6.2.3 STEPS OF A SURVEY USING THE WORLD HEALTH ORGANIZATION/HEALTH ACTION INTERNATIONAL METHODOLOGY -- 6.2.3.1 Presurvey Planning -- 6.2.3.2 Preparation of the Survey -- 6.2.3.3 Training of Area Supervisors, Data Collectors, and Data Entry Personnel -- 6.2.3.4 Preparing for Data Collection -- 6.2.3.5 Data Collection in the Field -- 6.2.3.6 Data Entry -- 6.2.3.7 Data Analysis and Interpretation -- 6.2.3.7.1 Availability -- 6.2.3.7.2 Prices -- 6.2.3.7.3 Affordability -- 6.2.3.8 Measuring Price Components -- 6.2.3.9 International Comparisons of Data from Surveys Undertaken Using the World Health Organization/Health Action International Methodology -- 6.2.3.10 Exploring Policy Options -- 6.2.3.11 Reporting -- 6.2.4 USE OF THE WORLD HEALTH ORGANIZATION/HEALTH ACTION INTERNATIONAL METHODOLOGY IN PRACTICE -- REFERENCES. 7 - Terminology - Is Talking About Definitions Boring, or Is It the Starting Point? -- LIST OF ABBREVIATIONS -- 7.1 PURPOSE -- 7.2 KEY TERMS -- 7.3 TRAINING MATERIAL: EXERCISES -- 7.3.1 Definitions - Multiple Choice Questions -- 7.3.2 Cloze test - Please Fill Out This Cloze Test by Adding the Missing Words -- 7.3.3 Crossword Puzzle -- REFERENCES -- 8 - Medicine Price Data Sources -- LIST OF ABBREVIATIONS -- 8.1 SELECTION OF MEDICINE PRICE DATA SOURCES -- 8.1.1 Taxonomy of Data Sources -- 8.1.2 Assessment of Data Sources -- 8.2 MEDICINE PRICE SERVICES AND DATABASES -- 8.2.1 Public Sector Data Sources -- 8.2.2 Collaborative Initiatives -- 8.2.2.1 Management Sciences for Health -- 8.2.2.2 Early Advances in Europe: European Commission's Projects -- 8.2.2.3 EURopean Integrated Price Information Database (Euripid) -- 8.2.2.4 Decisiones Informadas en Medicamentos Platform in Latin America -- 8.2.2.5 Western Pacific Platform for Procurement Prices -- 8.2.2.6 WHO Global Price Reporting Mechanism for HIV, Tuberculosis, and Malaria -- 8.2.2.7 Vaccine Product, Price, and Procurement Platform -- 8.2.3 Other Providers -- REFERENCES -- 9 - Preparing Price Studies - Key Methodological Decisions -- LIST OF ABBREVIATIONS -- 9.1 INTRODUCTION -- 9.2 PURPOSE AND PERSPECTIVE -- 9.3 KEY METHODOLOGICAL DECISIONS -- 9.3.1 Geographic Area -- 9.3.2 Sectors and Settings -- 9.3.3 Medicines -- 9.3.4 Price Data -- 9.3.4.1 Definitions of Medicine Price and `Price Proxies' -- 9.3.4.2 Units of Measurement -- 9.3.4.3 Price Types -- 9.3.4.3.1 Price Components along the Supply Chain -- 9.3.4.3.2 Reimbursement Prices -- 9.3.4.3.3 List Prices and Confidentiality -- 9.3.5 Time Period -- 9.3.5.1 Cross-sectional Studies -- 9.3.5.2 Time-Series Analyses -- 9.3.6 Specific Decisions Related to Cross-Country Comparisons -- 9.3.6.1 Comparator Countries -- 9.3.6.2 Comparable Medicines. 9.3.6.2.1 Strategies to Optimise Medicine Selection for Cross-Country Comparison -- 9.3.6.2.2 Like-for-Like Comparison -- 9.3.6.3 Comparable Price Types -- 9.3.6.4 Weighting for Volume (Price Indices) -- 9.3.6.5 Choice of Conversion Rate and Weighting for Income -- 9.4 LIMITATIONS AND CONCLUSIONS -- REFERENCES -- 10 - Training Exercises for Medicine Price Surveys, Analyses and Comparisons -- LIST OF ABBREVIATIONS -- 10.1 PURPOSE -- 10.2 TRAINING MATERIAL: EXERCISES -- 10.2.1 Exercise 1 - Preparation of the Study (Methodology) -- 10.2.2 Exercise 2 - Price Data Calculation -- 10.2.2.1 Q1: One of the Top-Selling Products Is Glupic -- 10.2.3 Exercise 3 - Price Data Presentation and Data Analysis -- 10.2.3.1 Q1: Price Differences to the Neighbouring Countries -- 10.2.3.2 Q2: Index Calculation -- 10.2.3.3 Q3: Box Plot Data Presentation -- 10.2.3.4 Q4: Prices in Purchasing Power Parities (PPP) -- REFERENCES -- 3 - Using Medicine Price Comparisons for Policy-Making -- 11 - Price Comparison as a Pricing Policy Option-Introduction into Pharmaceutical Policies -- LIST OF ABBREVIATIONS -- 11.1 NEED FOR PHARMACEUTICAL REGULATION AND POLICIES -- 11.1.1 Regulation-to Ensure Safety of Medicines and Pharmaceutical Provision -- 11.1.2 Pharmaceutical Policies-to Contribute to Affordable Access to Medicines -- 11.2 TAXONOMIES OF PHARMACEUTICAL POLICIES -- 11.3 INTRODUCTION INTO PRICING POLICIES -- 11.3.1 Medicines Groups -- 11.3.2 Sectors -- 11.3.3 Price Types -- REFERENCES -- 12 - Practice of External Price Referencing -- LIST OF ABBREVIATIONS -- 12.1 OVERVIEW OF USE OF EPR WORLDWIDE -- 12.1.1 Relevance of EPR -- 12.1.2 Reference Countries -- 12.1.3 Scope of Medicines -- 12.1.4 Price Types -- 12.1.5 Calculation Method -- 12.2 OVERVIEW OF USE OF EPR IN WHO EURO REGION -- 12.2.1 Relevance of EPR -- 12.2.2 Reference Countries -- 12.2.3 Scope of Medicines. 12.2.4 Price Types. |
| Record Nr. | UNINA-9910583013503321 |
| London, England : , : Elsevier, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The open pharmacoeconomics & health economics journal
| The open pharmacoeconomics & health economics journal |
| Pubbl/distr/stampa | [Hilversum], : [Bentham Science Publishers], [2009]-[2019] |
| Descrizione fisica | 1 online resource (7 volumes) |
| Soggetto topico |
Medical economics
Pharmaceutical industry - Economic aspects Pharmacology - Economic aspects Economics, Pharmaceutical Health Care Economics and Organizations |
| Soggetto genere / forma |
Periodical
Periodicals. |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti |
Open pharmacoeconomics and health economics journal
TOPHARMEJ Pharmacoeconomics & health economics journal |
| Record Nr. | UNINA-9910895765303321 |
| [Hilversum], : [Bentham Science Publishers], [2009]-[2019] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Pharmaceutical lifecycle management [[electronic resource] ] : making the most of each and every brand / / Tony Ellery, Neal Hansen
| Pharmaceutical lifecycle management [[electronic resource] ] : making the most of each and every brand / / Tony Ellery, Neal Hansen |
| Autore | Ellery Tony |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2012 |
| Descrizione fisica | 1 online resource (413 p.) |
| Disciplina | 338.4/76153 |
| Altri autori (Persone) | HansenNeal |
| Soggetto topico |
Pharmaceutical industry - Economic aspects
Drug approval - Economic aspects |
| ISBN |
1-280-59148-X
9786613621313 1-118-26589-0 1-118-26675-7 1-118-26679-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | pt. A. Lifecycle management business environment -- pt. B. Lifecycle management regulatory and legal environment -- pt. C. Patents and exclusivities -- pt. D. Developmental LCM -- pt. E. Commercial LCM -- pt. F. Biologics and biosimilars -- pt. G. The integrated brand LCM strategy and its implementation -- pt. H. Integrating LCM with portfolio management. |
| Record Nr. | UNINA-9910141272203321 |
|
Ellery Tony
|
||
| Hoboken, N.J., : John Wiley & Sons, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Pharmaceutical lifecycle management : making the most of each and every brand / / Tony Ellery, Neal Hansen
| Pharmaceutical lifecycle management : making the most of each and every brand / / Tony Ellery, Neal Hansen |
| Autore | Ellery Tony |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2012 |
| Descrizione fisica | 1 online resource (413 p.) |
| Disciplina | 338.4/76153 |
| Altri autori (Persone) | HansenNeal |
| Soggetto topico |
Pharmaceutical industry - Economic aspects
Drug approval - Economic aspects |
| ISBN |
9786613621313
9781280591488 128059148X 9781118265895 1118265890 9781118266755 1118266757 9781118266793 111826679X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | pt. A. Lifecycle management business environment -- pt. B. Lifecycle management regulatory and legal environment -- pt. C. Patents and exclusivities -- pt. D. Developmental LCM -- pt. E. Commercial LCM -- pt. F. Biologics and biosimilars -- pt. G. The integrated brand LCM strategy and its implementation -- pt. H. Integrating LCM with portfolio management. |
| Record Nr. | UNINA-9910817235003321 |
|
Ellery Tony
|
||
| Hoboken, N.J., : John Wiley & Sons, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
